Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

INTRODUCTION: Ibrutinib (ibr) monotherapy and the combination of obinutuzumab plus chlorambucil (obi) are approved for previously untreated chronic lymphocytic leukemia (CLL). No trials directly comparing their efficacy are available. Therefore a matching-adjusted indirect comparison (MAIC) was perf...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Adv Ther
Egile Nagusiak: Van Sanden, Suzy, Baculea, Simona, Diels, Joris, Cote, Sarah
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2017
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504213/
https://ncbi.nlm.nih.gov/pubmed/28573505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-017-0564-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak